We are live on ! Find out more
MLNT

Melinta Therapeutics
MLNT

Delisted

MLNT was delisted on the 10th of January, 2020.

78 hedge funds and large institutions have $183M invested in Melinta Therapeutics in 2017 Q4 according to their latest regulatory filings, with 78 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

36.96% more ownership

Funds ownership: 0% → 36.96% (+37%)

35% less call options, than puts

Call options by funds: $1.85M | Put options by funds: $2.84M

Holders
78
Holders Change
+78
Holders Change %
–
% of All Funds
1.76%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
78
Increased
–
Reduced
–
Closed
–
Calls
$1.85​M
Puts
$2.84​M
Net Calls
-⁠$985​K
Net Calls Change
-⁠$985​K

MLNT Hedge Fund Activity: Q4 2017 in Review

78 of the 4,421 institutional investors tracked by Wall St. Rank reported a position in Melinta Therapeutics (MLNT) for Q4 2017, worth a combined $183M.

Buyers outnumbered sellers: 78 funds opened new MLNT positions and 0 closed out — a net gain of 78 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Fidelity Investments, opening a new position worth an estimated $14.6M.

  • 78 institutional investors held Melinta Therapeutics (MLNT) as of Q4 2017, up from 0 in Q3 2017.
  • Funds reported $183M of Melinta Therapeutics stock for Q4 2017.
  • 78 funds opened new Melinta Therapeutics positions in Q4 2017 and 0 closed out, a net change of +78 holders.
  • The largest Melinta Therapeutics buyer in Q4 2017 was Fidelity Investments, an estimated $14.6M added.

Based on aggregated 13F filings for Q4 2017.